Member Info for undervaluedtoday

Https://ukinvestormagazine.co.uk/cellbxhealth-shares-soar-after-inking-agreement-with-astrazeneca/

News close by any chance 😏👊☝️

Very little stock around guys

Double digits incoming just hitting radars the last week with zero free float all time high incoming was 75-100p efore

Https://www.proactiveinvestors.co.uk/LON:CLBX/CelLBxHealth-PLC

TRY double digits more big stuff coming 😏👊

Broad Market Consensus

According to tracking data across aggregate platforms like London Stock Exchange ShareChat and ADVFN, analyst sentiment sits at a Strong Buy:

Conservative Average Target: 4.0p to 7.0p.

High-End Speculative Estimates: Up to 30.0p.

Valuation Forecast: Independent estimates (such as Trinity Delta) model the fundamental underlying value of the technology portfolio at up to £118 million, or roughly 37p per share, once wider commercial adoption by pharmaceutical groups is achieved

Master Services Agreement with Global Pharmaceutical Company

CTC-powered analytics for drug discovery and development

Guildford, UK and Plymouth Meeting, U.S. - 29 May 2026 - CelLBxHealth plc (AIM: CLBX), a CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, announces that it has entered into a Master Services Agreement with AstraZeneca.

The agreement establishes CelLBxHealth as a qualified service provider to AstraZeneca, enabling the Company to support drug discovery and development through CTC powered analytics of clinical trial samples using the Parsortix® platform.

Peter Collins, Chief Executive Officer of CelLBxHealth, commented: "We are delighted to enter into this Master Services Agreement which enables AstraZeneca to access our capabilities across their development pipeline. We look forward to delivering strong and productive outcomes through this framework."

Nuformix Advances Inhaled Fibrosis Therapy Following Orphan Drug Milestones and New Funding Support (NFX)

Fiona Craig

LSE:NFX

Market News

28 May 2026 9:18AM

Nuformix (LSE:NFX) reported interim results showing continued progress for NXP002, its lead inhaled treatment candidate targeting idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. The company recently secured U.S. FDA Orphan Drug Designation for the enabled form of tranilast used within the programme, adding to the European Medicines Agency orphan designation already granted for the therapy.

Management said the dual orphan status is helping to strengthen ongoing discussions with potential partners regarding licensing or broader collaboration opportunities. Preclinical studies have also continued to demonstrate strong anti-fibrotic and anti-inflammatory activity from NXP002, both as a standalone treatment and when used alongside existing standard-of-care therapies.

Improved Financial Position Supports Development Strategy

Nuformix reported a reduced half-year loss of £346,577, while loss per share improved to 0.02p. The company’s financial position was supported by a heavily oversubscribed open offer followed by a separate £1 million share subscription.

As a result, cash and cash equivalents increased to £930,283, while net assets rose to £1.64 million. The company said the newly raised funds are being directed toward generating additional value-enhancing data for NXP002 and refining the programme in line with feedback from prospective commercial partners.

Management believes this strategy could improve the prospects of securing an out-licensing agreement and help advance the programme toward clinical development in what is expected to become a rapidly expanding IPF treatment market.

ImmuPharma Reduces Losses and Strengthens Funding Position as P140 Autoimmune Programme Progresses (IMM)

Fiona Craig

LSE:IMM

Market News

27 May 2026 9:06AM

ImmuPharma (LSE:IMM) reported a reduced loss of £1.8 million for 2025, while maintaining broadly stable operating costs and ending the year with a cash balance of £1.4 million. The company subsequently strengthened its financial position through a £6.47 million equity fundraising completed in April 2026, providing additional support for the advancement of its development pipeline.

During the year, ImmuPharma continued progressing its P140 autoimmune platform through the generation of new mechanistic data, alongside the filing of a patent covering both a companion diagnostic and precision treatment approach targeting Type M immune disorders. The company is also preparing the platform for late-stage clinical development and potential licensing discussions. Management said these developments could position P140 as a potential future standard of care across several autoimmune disease indications, while ongoing talks with prospective partners are aimed at securing a value-enhancing licensing agreement during 2026.

ImmuPharma additionally advanced Kapiglucagon as a strategic metabolic disease asset by beginning IND-enabling studies and evaluating a potential 505(b)(2) regulatory pathway. The company also strengthened its leadership structure through internal scientific promotions and the appointment of a new independent non-executive director.

The company’s outlook continues to be weighed down by weak financial fundamentals, including minimal revenue generation, ongoing losses, persistent cash burn and negative shareholder equity. Technical indicators are mixed but moderately supportive relative to the long-term 200-day moving average, while valuation remains constrained by the absence of earnings and dividend yield support.

Moving up

CelLBxHealth plc is currently in the final stages of concluding a Master Services Agreement (MSA) with a top-ten global pharmaceutical company. The agreement will focus on using CelLBxHealth's Parsortix® platform to potentially support drug discovery and development.This milestone represents a significant expansion for the platform, leveraging the technology to isolate circulating tumor cells (CTCs) for advanced oncology and research.

In its May 2026 Q1 trading update, the company confirmed it is in the final stages of concluding a Master Services Agreement (MSA) with a top-ten global pharmaceutical company. This upcoming partnership is designed to deploy CelLBxHealth's proprietary Parsortix® platform to support drug discovery and development applications.

Strategic and Financial Impacts of the Pharma MSA Framework for Rapid Scaling: Securing an MSA creates an overriding legal and operational framework. According to historical company insights, this allows subsequent project-specific contracts to be greenlit and executed much faster without renegotiating core terms each time.Independent Commercial Validation: Corporate house brokers like Cavendish view this imminent deal as a crucial external validation of the Parsortix® platform. It establishes a precedent that is expected to drive broader adoption among other contract research organisations (CROs) and pharmaceutical peers

Buy

CLBX.L

Cellbxhealth PLC

Current price1.6990 1.8110

Quote price 1.8844

Order typeFixed price quote

Quantity1000000

Investment

Commission

£0.00

PTMLevy

£1.50

Consideration

£18,844.00

Total cost £18,845.50

Https://www.lse.co.uk/news/in-brief-nuformix-interim-loss-narrows-aims-to-raise-value-of-assets-vegbyc6oaxbby61.html

Nuformix PLC - London-based developer of treatments for fibrosis and oncology - Pretax loss narrows to GBP346,577 in the six months ended March 31, from GBP376,668 a year prior. Looking ahead, Nuformix says: "The company continues to advance and exploit the current assets within the portfolio through the research & development and business development activities as set out above. The strategy of the group is to continue to increase the value of its existing assets while maintaining tight control of costs, including conducting business development/licensing activities using a structured and data-driven approach, with the goal of seeking global licensing deals."

The company highlights that during the six months to March 31, the US Food & Drug Administration had granted orphan drug designation in idiopathic pulmonary fibrosis for tranilast lystate, the active drug substance enabled for inhaled delivery in NXP002, Nuformix's lead programme.

Current stock price: 0.17 pence each

12-month change: up 6.3%

By Tom Budszus, Alliance News slot editor

Breakdown of Analyst TargetsT he dual-listed mining exploration company has the following targets across key tracking platforms:Metric / ExchangeLSE / UK Target (GBX / Pence)ASX / Australian Target (AU$)Overall Consensus Average / Median Target GBX 739.59 – 781.28AU$ 14.63 – 14.77Moderate Buy / NeutralH igh Estimate GBX 817.32 – 1,026.59 AU$ 19.00

Recent Major Broker RatingsIndividual firm assessments from prominent investment firms highlight differing valuation assumptions:Citigroup: Boosted its price target to GBX 816 (from GBX 780) with a Neutral rating. For the Australian listing, Citi sets a Buy rating at AU$ 15.30.Royal Bank of Canada (RBC): Maintained a Buy rating, aggressively boosting its target to GBX 816 (from GBX 675). On the Australian side, RBC holds a Neutral/Hold outlook at AU$ 11.70.Macquarie: Maintains mixed coverage on the ASX listing, split between a Hold target of AU\( 13.50** and a **Buy** target at **AU\) 13.20.Canaccord Genuity: Reiterated a Buy rating with a price target of GBX 635.Core Growth & Operational Outlook Production Guidance: For the fiscal year, Greatland Resources expects production to hit or exceed the upper band of its 260,000 oz to 310,000 oz gold guidance range, at an All-In Sustaining Cost (AISC) of $2,400 to $2,800/oz.Resource Growth: Major Mineral Resource Estimate (MRE) expansions have concluded at the West Dome Open Pit (WDO) and Main Dome Underground (MDU) active mining regions.Earnings Projections: Analysts model regular revenue expansion at roughly 5.2% per annum, though bottom-line earnings are expected to decline slightly over the next three years by 1.6% per annum due to higher operational expenditures.

Wall Street and London stock analysts maintain a consensus "Strong Buy" rating for Quantum Helium Limited (LON: QHE) with a 12-month average price target of 10.01p (GBX). This represents a significant projected upside from its recent trading price of roughly 0.03p.

Because Quantum Helium is a micro-cap stock with thin trading volumes, consensus data varies across financial platforms depending on how specific data feeds aggregate currency values and individual analyst models.

Consensus Average Target 10.01p Stockopedia High Target Estimate 10.50p Stock Unlock

Consensus Rating: Wall Street trackers show a unanimous Buy / Strong Buy sentiment among reporting analysts, with zero "Hold" or "Sell" recommendations.Growth Projections: Long-term models hosted on Simply Wall St forecast Quantum Helium's annual earnings to grow by 45.5% per annum.Revenue Projections: Revenues are expected to expand at a steady rate of 3.7% per annum, while its Earnings Per Share (EPS) are projected to ramp up by 97.5% per annum.

Buy

CLBX.L

Cellbxhealth PLC

Current price1.6890 1.8010

Quote price1.8272

Order typeFixed price quote

Quantity750000

Investment

Commission

£0.00

PTMLevy

£1.50

Consideration

£13,704.00

Total cost £13,705.50

ImmuPharma PLC is actively seeking global partners to license its lead autoimmune therapy P140, aiming to finalize a deal in 2026. The company highlighted progress with a UK patent report and new study data, supporting its precision medicine approach with a companion diagnostic platform. Additionally, ImmuPharma is advancing Kapiglucagon, a drug for metabolic disease and Type 1 diabetes, preparing for FDA discussions. Financially, the company narrowed its loss to £1.8 million and strengthened cash reserves through a recent £6.47 million fundraise.

Cash Runway Extended: In April 2026, ImmuPharma secured a £6 million Lanstead subscription and WRAP retail offer. Management noted that this funding extends the company's financial runway to at least H2 2028.Corporate Milestones: The board labeled 2026 a "year of delivery", with its primary focus placed on locking in a high-value commercial partnering agreement for its lead autoimmune drug platform, P140 (targeting Lupus).Upside Benchmark: While not a formal analyst target, the Lanstead funding structure utilizes an 8.00p benchmark as its reference point for share performance returns, indicating where management hopes to drive value if upcoming clinical partnerships succeed.

28th May 2026

Nuformix plc

("Nuformix", the "Company" or the "Group")

Half Year Report

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces its unaudited results for the six months ended 31 March 2026.

Operational highlights

· The Board continues to believe that NXP002, Nuformix's lead programme, offers a potentially significant treatment for progressive fibrosing interstitial lung diseases ("ILDs"), including Idiopathic Pulmonary Fibrosis ("IPF") and Progressive Pulmonary Fibrosis ("PPF"), and is focused on generating data and further progressing on-going discussions with potential partners that is expected to support its efforts to secure a licensing, option or collaborative agreement for NXP002.

· During the period the Company announced that the U.S. Food and Drug Administration ("FDA") had granted Orphan Drug Designation ("ODD") in IPF for tranilast lystate, the active drug substance enabled for inhaled delivery in NXP002.

Financial Highlights

· Loss on ordinary activities (after tax credit) of £346,577 (31 March 2025: loss of £376,668)

· Loss per share 0.02p (31 March 2025: 0.03p)

· Net assets of £1,636,439 (31 March 2025: £807,653) including £930,283 of cash and cash equivalents at 31 March 2026 (31 March 2025: £97,911)

· In November 2025, an oversubscribed open offer raised gross proceeds of £228,081 through the issue of 114,050,535 new ordinary shares at a price of 0.2 pence per share.

· In March 2026, a subscription for 500,000,000 new ordinary shares at a price of 0.2 pence per share raised gross proceeds of £1,000,000.

Dr Dan Gooding, Executive Director of Nuformix, said: "Our on-going research efforts and progressive external discussions to date validate that inhaled treatment of IPF and related fibrotic lung diseases via NXP002 remains a viable and attractive concept. In March 2026 we were delighted to receive news of the FDA's award of Orphan Drug Designation in IPF for NXP002. Given the EMA's award of the same, these achievements support the plausibility of our differentiated approach, targeting fibrosis resolution and restoration of tissue function, whilst allowing healthy repair, which has been very helpful in advancing partnering discussions. The March placing proceeds are allowing us to generate value-enhancing data and progress the NXP002 programme, aligning with feedback from potential partners and supporting our focussed efforts to secure an out-licensing partner for NXP002. I remain excited by our future prospects and look forward to providing further updates in due course as appropriate."

TALK of a major deal with astrazeneca

CelLBxHealth plc (formerly ANGLE plc) is a UK-based precision oncology company that has partnered with AstraZeneca to develop and validate assays for cancer treatment monitoring. The collaboration focuses on using CelLBxHealth’s proprietary Parsortix® system to isolate circulating tumor cells (CTCs) from blood samples, providing a "liquid biopsy" alternative to traditional tissue biopsies.

Key Aspects of the AstraZeneca CollaborationAssay Development: CelLBxHealth has completed multiple contracts with AstraZeneca, specifically focusing on developing assays to detect DNA damage responses in CTCs.Prostate Cancer Studies: The partnership has included work on identifying specific biomarker alterations in castration-resistant prostate cancer (CRPC), such as androgen receptor (AR) changes.Technology Application: The Parsortix system captures intact CTCs, allowing AstraZeneca to analyze protein loss and gene expression (RNA) rather than just genetic mutations (DNA).Ongoing Relationship: As of early 2026, CelLBxHealth continues to leverage its GCLP-compliant laboratory in the UK for bespoke clinical trial support and assay development for pharmaceutical partners, including the previously established work with AstraZeneca.

CelLBxHealth (formerly ANGLE) ContextRebranding: In November 2025, ANGLE plc officially rebranded to CelLBxHealth plc to focus on "CTC intelligence" and high-value clinical diagnostics.Clinical Trials: The company has utilized its Parsortix system in significant clinical studies (e.g., INFORM, EMBER2) for breast, prostate, ovarian, and lung cancers.Commercial Focus: The company is focusing on commercializing its system for biopharma clinical services and lab-developed tests.The collaboration is part of a broader strategy for CelLBxHealth to partner with major pharmaceutical companies (including Eisai) and diagnostic companies like QIAGEN and Roche to implement CTC workflows in drug development.